TITXF News 2.1900 08/01/2014 05:41:36 Titan Medical Inc (TIT

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Titan Medical Inc (TITXF) 2.1900 $TITXF

With Only One Product to Hope For, the Source of Downside Risks Are Numerous and Diverse; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Mon Jun 30, 1:30PM CDT
Titan Medical Inc. (OTCQX: TITXF) is a venture company with a market capitalization of about $200 million. Headquartered in Toronto, Canada. The company is involved in building a robotic surgical tool for application in minimally invasive surgery ("MIS" . The key concept of MIS is to minimize the incision area during the surgical operation. In general, MIS leads to quicker recovery, shorter hospital stays, less pain, fewer and smaller scars, reduced risk of infection, and less blood loss.

Titan Medical Inc. Corporate Update
Marketwire Canada - Mon Jun 30, 6:00AM CDT
Titan Medical Inc. (the "Company" (TSX VENTURE:TMD) (OTCQX:TITXF) announced today that Mr. Joe Talarico, Senior Vice President Business Development has resigned his position with the Company. We would like to thank Joe for his contribution to Titan during his four years with the Company. In the interim John Hargrove, Chairman and CEO will assume the responsibilities for Business Development.

Titan Medical Inc. Retains New York-Based Bertner Advisors, LLC for Investor Relations Services
Marketwire - Wed Jun 18, 1:29AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it has retained Bertner Advisors, LLC as its investor relations advisor. Services to be provided in the United States to Titan by Bertner Advisors include counsel on investor relations strategy.

Titan Medical Inc. Announces Completion of Key Milestone in the Development of Its SPORT(TM) Surgical System
Marketwire - Mon Jun 16, 6:01AM CDT
Titan Medical Inc. (the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today that it successfully completed animal tissue studies on May 30, 2014, performing a full cholecystectomy (gallbladder removal) procedure using the SPORT Surgical System alpha commercial prototype for the required surgical tasks (including grasping, dissecting, mono-polar cautery and suturing). This comes after the recent successful completion of the Q1 2014 milestone of completing an alpha commercial prototype. "We are most pleased to confirm this key milestone of the successful completion of an actual non-human surgical procedure. The procedure was extensively validated by reviewing video footage of the surgical field and instruments from several viewing angles," said John Hargrove, Titan Medical Chairman and CEO. He further stated, "This is what we expected and targeted for our goals-we have a great team, a great technology and a tremendous opportunity. The development of the SPORT Surgical System remains on schedule."

Titan Medical Inc. Announces Results for the Three Months Ended March 31, 2014, in U.S. Dollars
Marketwire - Wed May 21, 12:56PM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today its results for the three months ended March 31, 2014.

Titan Medical Releases SPORT(TM) Video Clip-"SPORT Tackles Complex Surgical Tasks"
Marketwire - Tue May 20, 6:32AM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) is pleased to provide an update on the ongoing progress of the Single Port Orifice Robotic Technology (SPORT(TM)) Surgical System. Today, the Company is releasing a video clip demonstrating electrocautery, tissue suturing and instrument swaps. The video may be viewed at www.titanmedicalinc.com.

Medical Robots Market by Type & Application - Global Forecasts to 2018 for the $1,781 Million Market
M2 - Fri Mar 21, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwj8xd/medical_robots) has announced the addition of the "Medical Robots Market by Type (Surgical Robot, Rehabilitation Robotics, Telemedicine, Assistive Robots, Orthotics, Prosthetics, Radio Surgery, Exoskeleton) & Application (Orthopedic, Neurology, Laparoscopy)- Global Forecasts to 2018" report to their offering. The medical robotics market was valued at $1,781 million in 2013 and is expected to reach $3,764 million by 2018, growing at a CAGR of 16.1% from 2013 to 2018 Over the years, the demand for medical robots has increased significantly. This is due to the paradigm shift in the healthcare industry where emphasis is being laid on minimally invasive surgeries through the use of robots. The global medical robot market is categorized into five broad segments - surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and others. Based on applications, the medical robots market comprises the following segments - neurology, orthopedics, laparoscopy, special education, and other areas. . The hospital and pharmacy robots segment is the fastest-growing segment of the medical robotics market. The increasing demand for telemedicine robots is likely to propel the growth of this market. Along with this, technological developments and increasing adoption of newer technologies by hospitals are some factors that are propelling the demand for hospital and pharmacy robots. The other major segment under hospital and pharmacy robots is the i.v. robots segment. i.v. robots are dispensing robots used in hospitals and pharmacies to accurately compound drug mixtures. These robots are used to administer safe, accurate, efficient, cost-effective, and ready-to-administer IV admixtures. Factors such as an aging population, increasing spending power of the middle-class population, increasing number of private sector hospitals, advancements in endoscopic technologies, and expansions of rural healthcare facilities are also going to play a pivotal role in boosting the demand for medical robotics in the Asian region. China and Japan will be the focal point for the growth of medical robotics in the Asian market. Countries such as Singapore and Thailand are also expected to witness growth in this sector, owing to increasing government support. North America and Europe are both likely to witness an increasing demand for medical robotics owing to technological advancements as well as increased government support in both the geographies. Scope of the Report Segment - Surgical Robots -- Orthopedic Surgical Robots -- Neurological Surgical Systems -- Laparoscopy Robotic Systems -- Steerable Robotic Catheters - Rehabilitation Robots -- Assistive Robots -- Prosthetics -- Orthotics -- Therapeutic Robots -- Exoskeleton Robotic Systems - Non-Invasive Radio surgery Robots - Hospital and Pharmacy Robots -- Telemedicine Robots -- I.V. Robots -- Pharmacy Robots - Others Application - Neurology - Orthopedics - Laparoscopy - Special Education - Others Companies Mentioned - Accuray, Inc. - Hansen Medical, Inc. - Health Robotics S.R.L. - Intuitive Surgical Inc. - Mako Surgical Corp. - Mazor Robotics Ltd. - Medrobotics Corporation - Or Productivity Plc - Renishaw Plc - Titan Medical Inc. For more information visit http://www.researchandmarkets.com/research/mw...cal_robots

Titan Medical Inc. Appoints Dr. Bruce Wolff to the Board of Directors
Marketwire - Tue Mar 11, 3:04PM CDT
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) is pleased to announce that Dr. Bruce Giles Wolff, M. D., Professor of Surgery, Mayo Clinic College of Medicine and Emeritus Chair of the Division of Colon & Rectal Surgery, Mayo Clinic - Rochester, Minn., has been appointed to the Board of Directors. Dr. Wolff has been a member of the Mayo Clinic's Surgical Administrative Committee since 2006. Dr. Wolff is a former President of the American Society of Colon and Rectal Surgeons, a former Director and President of the American Board of Colon and Rectal Surgery, and a former Vice President and Director of the Foundation for Surgical Fellowships. Dr. Wolff has written extensively on colon and rectal surgery issues in almost 300 articles for publications such as The American Journal of Surgery, the Canadian Journal of Surgery, the World Journal of Surgery, Mayo Clinic Proceedings, the America Surgeon, the Journal of Gastrointestinal Surgery, Diseases of the Colon & Rectum, Annals of Surgery and the British Journal of Surgery.

Titan Medical Inc. Announces Results for Fiscal Year Ended December 31, 2013
Marketwire - Thu Mar 06, 4:54PM CST
Titan Medical Inc. ("Titan" or the "Company" (TSX VENTURE: TMD)(OTCQX: TITXF) announced today its results for the fiscal year ended December 31, 2013.

IIROC Trading Resumption - TMD, TMD.WT, TMD.WT.A, TMD.WT.B, TMD.WT.C
CNW Group - Wed Feb 19, 9:56AM CST
Trading resumes in:

IIROC Trading Halt - TMD, TMD.WT, TMD.WT.A, TMD.WT.B, TMD.WT.C
CNW Group - Wed Feb 19, 8:39AM CST
The following issues have been halted by IIROC:

IIROC Trade Halt - Titan Medical Inc.
Newsfile Corp - Wed Feb 19, 8:35AM CST
The following issues have been halted by IIROC:

IIROC Trade Resumption - Titan Medical Inc.
Newsfile Corp - Fri Feb 07, 12:43PM CST
Trading resumes in:

IIROC Trading Resumption - TMD TMD.WT TMD.WT.A TMD.WT.B TMD.WT.C
CNW Group - Fri Feb 07, 12:34PM CST
Trading resumes in:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading